[Isolation and analysis of the drug resistance of the flavobacterium and its production of beta-lactamases].
OBJECTIVE
To investigate the drug resistance of flavobacterium and its ability to produce BLA (beta-lactamases) and ESBLs (Extended-spectrum beta-lactamases).


METHODS
The production of BLA and ESBLs from 6 clinical isolated flavobacterium strains was determined by nitrocefin disc test and double-disc synergy method, respectively. The antibiotic susceptibilities of the strains were determined by Kirby-Bauer disc diffusion test and the agar dilution method and the MIC was assessed.


RESULTS
All the six flavobacteria were BLA-producing strains and more than 80% of them were ESBLs-producing, and they were highly resistant to beta-lactamase antibiotics (MIC 32 - 256 mg/L), but susceptible to fluoroquinolones and cephalosporin with beta-lactamase inhibitors (MIC 0.125 - 8 mg/L).


CONCLUSIONS
Most of the flavobacteria in nosocomial infections were beta-lactamase-producing and were highly resistant to beta-lactamase antibiotics. Fluoroquinolones and beta-lactamase antibiotics with lactamase inhibitors should be the first choice for the management of infection caused by flavobacterium.
Luo
Yu
Y
National Base for Drug Clinical Trial, Southwest Hospital, The Third Military Medical University, Chongqing, 400038. P.R. China.
Xia
Pei-yuan
PY
Wang
Xian-yuan
XY
Yin
Chun-hong
CH
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D024881:Drug Resistance, Bacterial / Q000187:drug effects; D005417:Flavobacterium / Q000187:drug effects* / Q000201:enzymology*; D006801:Humans; D008565:Membrane Proteins / Q000032:analysis* / Q000378:metabolism; D008826:Microbial Sensitivity Tests; D012269:Ribosomal Proteins / Q000032:analysis* / Q000378:metabolism
D000900:Anti-Bacterial Agents; D008565:Membrane Proteins; D012269:Ribosomal Proteins